PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces Second Quarter 2016 Financial Results
- European Commission Granted Orphan Drug Designation for Brincidofovir for the Treatment of Adenovirus - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet
View HTML
Toggle Summary Chimerix to Announce Second Quarter 2016 Financial Results on August 8, 2016
DURHAM, N.C. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2016 at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium
DURHAM, N.C. , June 07, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey , M.D., M.P.H., President and Chief Executive Officer of Chimerix , will participate in a
View HTML
Toggle Summary Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results
- Maintains strong financial position with $314.5 million in capital at quarter end - - Company to hold conference call at 8:30am ET today - DURHAM, N.C. , May 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical
View HTML
Toggle Summary Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016
DURHAM, N.C. , May 03, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, May 9, 2016 at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Present at the Barclays Global Healthcare Conference
DURHAM, N.C. , March 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that Linda M. Richardson , Chief Commercial Officer of Chimerix , will present at the Barclays Global Healthcare
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 36th Annual Health Care Conference
DURHAM, N.C. , March 01, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey , M.D., M.P.H., President and Chief Executive Officer of Chimerix , will present at the 36
View HTML
Toggle Summary Chimerix Announces Fourth Quarter and Full Year 2015 Financial Results
- Company to hold conference call at 8:30am ET today - - Survival and other key data from AdVise and matched controls to be reviewed with regulators in Summer 2016 - DURHAM, N.C. , Feb. 29, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral
View HTML
Toggle Summary Chimerix to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
DURHAM, N.C. , Feb. 22, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, February 29, 2016 at 8:30 a.m.
View HTML
Toggle Summary Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings
Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting  Despite Trial Not Meeting Primary Endpoint Company to Host Conference Call on February 22 at 8:00 a.m. EST to Provide Additional Analyses and Plans for Further Clinical Development DURHAM, N.C. , Feb.
View HTML